Zentalis Pharmaceuticals (NASDAQ:ZNTL) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a sell rating to a strong sell rating in a research note released on Saturday morning.

A number of other brokerages have also recently commented on ZNTL. Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.75.

Zentalis Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ ZNTL opened at $4.15 on Friday. The stock has a market cap of $297.43 million, a price-to-earnings ratio of -2.13 and a beta of 1.92. Zentalis Pharmaceuticals has a 1-year low of $1.21 and a 1-year high of $6.95. The stock’s 50-day moving average is $4.32 and its 200 day moving average is $3.61.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.10). On average, analysts forecast that Zentalis Pharmaceuticals will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Sivia Capital Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter worth about $27,000. CTC Alternative Strategies Ltd. bought a new position in shares of Zentalis Pharmaceuticals during the first quarter valued at $29,000. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at $37,000. Voleon Capital Management LP purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at $41,000. Finally, State of Wyoming purchased a new stake in shares of Zentalis Pharmaceuticals during the first quarter valued at $67,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.